News | September 24, 2010

SPIRIT IV Continues to Show Excellent Outcomes for Everolimus Stents

September 24, 2010 - Two-year data from the SPIRIT IV trial show that everolimus-eluting stents demonstrated enhanced safety and efficacy in treating de novo native coronary artery lesions when compared to paclitaxel-eluting stents.

SPIRIT IV is the largest clinical trial to date comparing two drug-eluting stents, with nearly 4,000 patients in the United States. The trial compared Abbott's Xience V everolimus-eluting coronary stent system with the Taxus Express2 paclitaxel-eluting coronary stent system. It also examined the differences in performance of the two stents in patients with diabetes. The results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 meeting in Washington, D.C.

Target lesion failure (TLF) at two years was 30 percent lower in the everolimus-eluting stent (6.9 percent versus 9.9 percent), and ischemia-driven target lesion revascularization (TLR) was also significantly reduced (4.5 percent versus 6.9 percent). In addition to lowering TLF and TLR, the everolimus-eluting stent also reduced the occurrence of heart attacks and stent thrombosis when compared to the paclitaxel-eluting stent.

In patients with diabetes there was a non-significant difference in the rate of TLF.

“The safety and efficacy of the everolimus-eluting stent compared to the paclitaxel-eluting stent, which were established at one year, are sustained at two years,” said Gregg W. Stone, M.D., professor of medicine at Columbia University College of Physicians and Surgeons, director of cardiovascular research and education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center and co-director of the medical research and education division at the Cardiovascular Research Foundation. Stone is also the principal investigator of the SPIRIT IV trial.

“These are significant findings that support the enhanced clinical outcomes achieved with the everolimus-eluting stent, which is the most commonly used drug-eluting stent,” he added.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init